Press Release no: 47/2015
Nordic Nanovector ASA (OSE: NANO) notes that its poster reporting
results from preclinical studies comparing the murine HH1 anti-CD37
antibody (the tumour-targeting component of Betalutin®) and the chimeric
version of the HH1 antibody (chHH1), is available on the Nordic
Nanovector website under Product Info/Scientific Posters.
The presentation of these results was given by Nordic Nanovector’s Chief
Scientific Officer, Jostein Dahle, at the recent European Association of
Nuclear Medicine (EANM) conference, which took place in Hamburg,
Germany, and noted in the Company’s third quarter report published on 21
October.
In the preclinical studies, chHH1 was shown to have certain properties
that may open up new opportunities in the treatment of B-cell lymphomas:
• Internalisation and selectivity to human lymphoid tissues of the two
antibodies were similar
• chHH1 induced antibody directed cellular cytotoxicity and was more
effective than murine HH1 in mice with Mantle Cell Lymphoma
• chHH1 was predicted to be less immunogenic than HH1
These findings suggest that an antibody radionuclide conjugate (ARC)
comprising chHH1 conjugated to lutetium-177:
• Has the potential for repeated doses over time, due to limited risk of
anti-drug antibody production
• Has a direct cytotoxic effect on cancer cells
• Can be explored as a frontline treatment of B-cell lymphomas
Nordic Nanovector is investigating further the potential of the chimeric
HH1 in a preclinical programme with the intention, if successful, of
taking it forward into clinical studies.
Dr Dahle commented: “These promising results, while early stage, suggest
that further investigation of our chHH1 ARC programme is warranted to
explore its potential to complement and extend the range of B-cell
tumours that we are investigating in the clinic with Betalutin.”
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company’s lead clinical-stage product opportunity is
Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates
(ARC) designed to improve upon and complement current options for the
treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with
substantial unmet medical need and orphan drug opportunities,
representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1)
conjugated to a low intensity radionuclide (lutetium-177). The
preliminary data has shown promising efficacy and safety profile in an
ongoing Phase 1/2 study in a difficult-to-treat NHL patient population.
The Company is aiming at developing Betalutin® for the treatment of
major types of NHL with first regulatory submission anticipated in 1H
2019.
Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets,
while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its ARC pipeline to
treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20151027006331/en/
Copyright Business Wire 2015